[1] |
中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 自身免疫性表皮下大疱病诊疗共识(2022)[J]. 中华皮肤科杂志, 2022,55(1):1⁃11. doi: 10.35541/cjd.20210532.
|
[2] |
Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)[J]. J Eur Acad Dermatol Venereol, 2022,36(10):1689⁃1704. doi: 10.1111/jdv.18220.
|
[3] |
Kirtschig G, Singh S. Interventions for bullous pemphigoid: summary of a Cochrane review[J]. Br J Dermatol, 2024,190(2):277⁃279. doi: 10.1093/bjd/ljad386.
|
[4] |
Kawahira H, Fujii K, Higashi Y, et al. Double filtration plasmapheresis for bullous pemphigoid: outcomes from the evaluation of eight patients[J]. Ther Apher Dial, 2023,27(6):1048⁃1050. doi: 10.1111/1744⁃9987.14052.
|
[5] |
Oren⁃Shabtai M, Mimouni D, Nosrati A, et al. Biological treatment for bullous pemphigoid[J]. Front Immunol, 2023,14:1157250. doi: 10.3389/fimmu.2023.1157250.
|
[6] |
Lin Z, Zhao Y, Li F, et al. Efficacy and safety of biological agents for pemphigoid: a systematic review and meta⁃analysis[J]. Int J Dermatol, 2023,62(8):1000⁃1008. doi: 10.1111/ijd. 16678.
|
[7] |
Jiang W, Ma X, Guo T, et al. Abrocitinib⁃a promising option for patients with refractory bullous pemphigoid[J]. J Eur Acad Dermatol Venereol, 2024,38(1):e119⁃e121. doi: 10.1111/jdv. 19475.
|
[8] |
Su F, Wang T, Qin Q, et al. Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review[J]. J Dermatolog Treat, 2024,35(1):2302394. doi: 10.1080/09546634.2024.2302394.
|
[9] |
Huang D, Zhang Y, Kong L, et al. Janus kinase inhibitors in autoimmune bullous diseases[J]. Front Immunol, 2023,14:1220887. doi: 10.3389/fimmu.2023.1220887.
|
[10] |
Qi W, Rushan X. The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China[J]. Int Immunopharmacol, 2023,118:110050. doi: 10.1016/j.intimp.2023.110050.
|
[11] |
Huang D, Zhang Y, Yu Y, et al. Long⁃term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study[J]. Int Immunopharmacol, 2023,125(Pt A):111157. doi: 10.1016/j.intimp.2023.111157.
|
[12] |
Le ST, Herbert S, Haughton R, et al. Rituximab and omalizumab combination therapy for bullous pemphigoid[J]. JAMA Dermatol, 2024,160(1):107⁃109. doi: 10.1001/jamadermatol.2023.4508.
|
[13] |
Amagai M, Ikeda S, Hashimoto T, et al. A randomized double⁃blind trial of intravenous immunoglobulin for bullous pemphigoid[J]. J Dermatol Sci, 2017,85(2):77⁃84. doi: 10.1016/j.jdermsci. 2016.11.003.
|
[14] |
Chebani R, Lombart F, Chaby G, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first⁃line therapy: a French national multicentre retrospective study of 100 patients[J]. Br J Dermatol, 2024,190(2):258⁃265. doi: 10.1093/bjd/ljad369.
|
[15] |
Zhao L, Wang Q, Liang G, et al. Evaluation of dupilumab in patients with bullous pemphigoid[J]. JAMA Dermatol, 2023,159(9):953⁃960. doi: 10.1001/jamadermatol.2023.2428.
|
[16] |
Moghadam P, Tancrede E, Bouaziz JD, et al. Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients[J]. Br J Dermatol, 2023,189(2):244⁃246. doi: 10.1093/bjd/ljad136.
|
[17] |
Manzo Margiotta F, Fidanzi C, Bevilacqua M, et al. Effectiveness and safety of dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid[J]. Skin Res Technol, 2023,29(10):e13488. doi: 10.1111/srt.13488.
|
[18] |
Liu Y, Wang Y, Zhang J, et al. Risk factors predisposing relapse of bullous pemphigoid at initial diagnosis: a retrospective cohort study of 205 patients[J]. Int Immunopharmacol, 2023,125(Pt A):111082. doi: 10.1016/j.intimp.2023.111082.
|
[19] |
Fenne IJ, Askildsen Oftebro G, Vestergaard C, et al. Effect of early initiation of steroid⁃sparing drugs in patients with bullous pemphigoid[J]. Front Immunol, 2023,14:1176284. doi: 10.3389/fimmu.2023.1176284.
|
[20] |
Learned C, Cohen SR, Cunningham K, et al. Long⁃term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: a multicenter retrospective review[J]. J Am Acad Dermatol, 2023,89(2):378⁃382. doi: 10.1016/j.jaad.2023. 03.036.
|
[21] |
Awethe Z, Viveiros M, Kaffenberger J. Durability of long⁃term immunomodulating medications in the treatment of bullous pemphigoid[J]. J Am Acad Dermatol, 2023,89(6):1287⁃1289. doi: 10.1016/j.jaad.2023.08.019.
|
[22] |
Huttelmaier J, Benoit S, Goebeler M. Comorbidity in bullous pemphigoid: up⁃date and clinical implications[J]. Front Immunol, 2023,14:1196999. doi: 10.3389/fimmu.2023.1196999.
|
[23] |
Tzanani I, Tzachy⁃Suissa I, Barzilai A, et al. Bullous pemphigoid and dipeptidyl peptidase⁃4 inhibitors: evaluation of clinical course and treatment response[J]. Clin Exp Dermatol, 2023,48(8):873⁃880. doi: 10.1093/ced/llad128.
|
[24] |
Jiirasutat N, Pongchareon P, Weschawalit S. Bullous pemphigoid and diabetes mellitus: a systematic review and meta⁃analysis[J]. Int J Dermatol, 2024,63(5):572⁃579. doi: 10.1111/ijd.16970.
|
[25] |
Li H, Wang H, Qiao G, et al. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: a case report and review of the literature[J]. Int Immunopharmacol, 2023,122:110591. doi: 10.1016/j.intimp.2023.110591.
|
[26] |
He MJ, Wang YJ, Ran DL, et al. Relationship between bullous pemphigoid and malignancy: a Mendelian randomization study[J]. J Dermatol, 2024,51(3):403⁃408. doi: 10.1111/1346⁃8138.17100.
|
[27] |
Baum S, Steinberg S, Tzanani I, et al. Prevalence, spectrum and clinical implications of malignancies in patients with bullous pemphigoid[J]. Acta Derm Venereol, 2023,103:adv00888. doi: 10.2340/actadv.v103.3979.
|
[28] |
Varpuluoma O, Jokelainen J, Huilaja L, et al. Solid and hematological malignancies in patients with bullous pemphigoid: a national cohort study[J]. J Am Acad Dermatol, 2024,90(2):399⁃401. doi: 10.1016/j.jaad.2023.09.073.
|
[29] |
Hansen I, Gebhardt C, Booken N, et al. Successful treatment of checkpoint inhibitor⁃associated bullous pemphigoid with dupilumab in a patient with angiosarcoma[J]. J Dtsch Dermatol Ges, 2024,22(4):587⁃589. doi: 10.1111/ddg.15340.
|
[30] |
Vičić M, Marinović B. Autoimmune bullous diseases in pregnancy: an overview of pathogenesis, clinical presentations, diagnostics and available therapies[J]. Ital J Dermatol Venerol, 2023,158(2):99⁃109. doi: 10.23736/S2784⁃8671.23.07553⁃9.
|
[31] |
Fang H, Li Q, Wang G. The role of T cells in pemphigus vulgaris and bullous pemphigoid[J]. Autoimmun Rev, 2020,19(11):102661. doi: 10.1016/j.autrev.2020.102661.
|
[32] |
Chen HC, Wang CW, Toh WH, et al. Advancing treatment in bullous pemphigoid: a comprehensive review of novel therapeutic targets and approaches[J]. Clin Rev Allergy Immunol, 2023,65(3):331⁃353. doi: 10.1007/s12016⁃023⁃08973⁃1.
|
[33] |
Olbrich H, Sadik CD, Schmidt E. Autoimmune blistering diseases: promising agents in clinical trials[J]. Expert Opin Investig Drugs, 2023,32(7):615⁃623. doi: 10.1080/13543784. 2023.2242778.
|